Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
5 State of the art Advancements in Computer generated Simulation - 2I asked ChatGPT who would win a Golden Globes. Here's what it got right — and totally wrong.
- 3Scientists sent a menstrual cup to space. This is how it went
- 4FDA approves Wegovy pill for weight loss: What to know
- 580 km. on foot: Sharren Haskel’s three-day march in protest of haredi draft bill
- Figure out How to Alter Your Volvo XC40 for Further developed Solace
- 100 new alien worlds: Scientists find hidden haul in data from NASA exoplanet-hunting spacecraft
- Carnival fever hits Lagos as locals celebrate Afro-Brazilian heritage
- Displaced Palestinian families suffer as heavy rains flood Gaza tent camps
- Archaeologists uncover details about the Hjortspring boat's origins
- Manual for Picking the Ideal Wine Matching
- Lower-cost space missions like NASA's ESCAPADE are starting to deliver exciting science – but at a price in risk and trade‑offs
- California warns of death cap mushrooms outbreak resulting in 3 deaths
- Iran Used $2 Billion in Crypto to Run Its Militant Proxies in 2025
